Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Valeo Pharma Inc T.VPH.DB


Primary Symbol: T.VPH Alternate Symbol(s):  VPHIF

Healthcare
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler,... see more

Recent & Breaking News (TSX:VPH)

VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023

Canada NewsWire May 25, 2023

VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS

Canada NewsWire April 28, 2023

VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE

Canada NewsWire April 19, 2023

VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023

Canada NewsWire March 15, 2023

VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST

Canada NewsWire March 9, 2023

VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC

Canada NewsWire February 7, 2023

VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022

Canada NewsWire January 30, 2023

VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS

Canada NewsWire January 26, 2023

VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST

Canada NewsWire January 25, 2023

VALEO PHARMA ANNOUNCES SENIOR MANAGEMENT CHANGE

Canada NewsWire November 21, 2022

VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE

Canada NewsWire November 15, 2022

Valeo (TSX:VPH) signs agreement for COVID treatment

Caroline Egan  September 14, 2022

VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

PR Newswire September 14, 2022

VALEO PHARMA REPORTS RECORD THIRD QUARTER 2022 RESULTS AND HIGHLIGHTS

Canada NewsWire September 13, 2022

VALEO PHARMA TO HOST THIRD QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST

Canada NewsWire September 9, 2022

VALEO PHARMA ADDS PHARMACEUTICAL INDUSTRY VETERAN KYLE STEIGER TO LEADERSHIP TEAM

Canada NewsWire August 30, 2022

Valeo Pharma (TSX:VPH) partners with Novartis

Trevor Abes  August 2, 2022

VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS

Canada NewsWire August 2, 2022

VALEO PHARMA ENTERS INTO LICENSE AGREEMENT WITH KALÉO FOR THE CANADIAN RIGHTS TO ALLERJECT®

Canada NewsWire August 2, 2022

VALEO PHARMA ENTERS INTO AN AGREEMENT FOR OPHTHALMIC PRODUCTS, PrXIIDRA® AND PrSIMBRINZA®, IN CANADA

Canada NewsWire August 2, 2022